[Federal Register: August 18, 2003 (Volume 68, Number 159)]
[Page 49488]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]



Food and Drug Administration

[Docket No. 2003N-0294]

Anesthetic and Life Support Drugs Advisory Committee; Amendment 
of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.


    The Food and Drug Administration (FDA) is announcing an amendment 
to the notice of meeting of the Anesthetic and Life Support Drugs 
Advisory Committee. This meeting was announced in the Federal Register 
of July 31, 2003 (68 FR 44955). The amendment is being made to reflect 
a change in the Agenda portion of the document. There are no other 

FOR FURTHER INFORMATION CONTACT: Johanna M. Clifford, Center for Drug 
Evaluation and Research (HFD-21), Food and Drug Administration, 5600 
Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), 
Rockville, MD 20857, 301-827-7001, or FDA Advisory Committee 
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC 
area), code 12529. Please call the Information Line for up-to-date 
information on this meeting.

SUPPLEMENTARY INFORMATION: In the Federal Register of July 31, 2003, 
FDA announced that a meeting of the Anesthetic and Life Support Drugs 
Advisory Committee would be held on September 9 and 10, 2003. On page 
44956, in the first column, the Agenda portion of the meeting is 
amended to read as follows:
    Agenda: On September 10, 2003, the committee will discuss the abuse 
liability of and Risk Management Plans for Palladone (Hydromorphone 
Hydrochloride) Purdue Pharma, LP, a modified-release hydromorphone drug 
product indicated for the treatment of moderate to severe pain in 
opioid tolerant patients.
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

    Dated: August 12, 2003.
Peter J. Pitts,
Associate Commissioner for External Relations.
[FR Doc. 03-20951 Filed 8-15-03; 8:45 am]